This article first appeared on GuruFocus .
Release Date: February 11, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Hikal Ltd ( BOM:524735 ) reported a consolidated revenue of 494 crores for Q3, indicating a return to operational profitability.
-
The company has successfully navigated regulatory scrutiny and is transitioning to optimal capacity utilization.
-
Hikal Ltd ( BOM:524735 ) has a diversified portfolio and long-standing customer partnerships, which help mitigate market uncertainties.
-
The pharmaceutical segment showed significant improvement with a revenue of 337 crores and a margin of 12.3%.
-
Investments in R&D and new facilities, such as the high potency laboratory and pilot plant, are expected to drive future growth.
Negative Points
-
The global crop protection segment is facing pricing pressures and structural overcapacity, impacting margins.
-
The company is still dealing with the aftermath of regulatory challenges, particularly concerning the US FDA audit.
-
There is ongoing volatility in procurement decisions and supply chain dynamics due to evolving trade policies.
-
Despite improvements, the crop protection segment recorded a low EBIT margin of 3%, indicating ongoing challenges.
-
The company has faced delays in achieving its growth targets due to regulatory and market challenges, impacting short-term performance.
Q & A Highlights
-
Warning! GuruFocus has detected 6 Warning Signs with BOM:524735.
-
Is BOM:524735 fairly valued? Test your thesis with our free DCF calculator.
Q: What is the status of the remediation plan submitted to the US FDA, and when can we expect a reinspection? A: We have submitted a remediation plan to the US FDA and provide updates every six weeks. The last updates were on December 16th and February 9th. We expect to hear back from the FDA in the next two weeks regarding their satisfaction with our progress. (Answered by Unidentified_3)
Q: How are the recent Chinese government policies affecting Hikal, particularly in the agrochemical sector? A: Currently, we do not see a significant impact from Chinese policies on our imports. Our procurement from China is minimal, and we are closely monitoring the situation. (Answered by Unidentified_2)
Q: Can you provide details on the investment and future plans for the HP API lab? A: We have invested approximately 10-11 crores in the HP API lab for phase one. In FY28, we plan to build a commercial-scale plant. We have started offering ADC services at the lab, and the plant will cater to both HP APIs and ADCs. (Answered by Unidentified_2 and Unidentified_3)
Q: What is the outlook for the animal health business, and can it reach 500 crores in the next few years? A: We aim to build the animal health business to over 500 crores in the next 4-5 years. The current pipeline is strong, and we are optimistic about growth, supported by a robust RFP base and commercial pipeline. (Answered by Unidentified_4)
Q: What is the guidance for the pharma and crop protection businesses for FY26 and beyond? A: The pharma business growth has been delayed due to the US FDA impact, but we expect growth to resume next year. Crop protection is expected to remain flat compared to last year. We anticipate improved performance in FY27 as the worst is behind us, and we have strengthened operations and diversified our product portfolio. (Answered by Unidentified_2)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
